National Cancer Institute

Работ: 10

1. Flanvotumab

   National Cancer Institute

   ДругоеCancer Immunotherapy and BiomarkersDefinitions2020Цитирований: 0

   ABIABI:AkademIndex/openalex/2020.other.000087

2. Anetumab

   National Cancer Institute

   ДругоеMyeloproliferative Neoplasms: Diagnosis and TreatmentDefinitions2020Цитирований: 0

   ABIABI:AkademIndex/openalex/2020.other.000089

3. Narnatumab

   National Cancer Institute

   ДругоеCancer Immunotherapy and BiomarkersDefinitions2020Цитирований: 0

   ABIABI:AkademIndex/openalex/2020.other.000090

4. Catumaxomab

   National Cancer Institute

   ДругоеMultiple Myeloma Research and TreatmentsDefinitions2020Цитирований: 0

   ABIABI:AkademIndex/openalex/2020.other.000091

5. Ombitasvir

   National Cancer Institute

   ДругоеSystemic Lupus Erythematosus ResearchDefinitions2020Цитирований: 0

   ABIABI:AkademIndex/openalex/2020.other.000092

6. Gerbil Fibrosarcoma

   National Cancer Institute

   ДругоеSarcoma Diagnosis and TreatmentDefinitions2020Цитирований: 0

   ABIABI:AkademIndex/openalex/2020.other.000093

7. Anetumab Ravtansine

   National Cancer Institute

   ДругоеMultiple Myeloma Research and TreatmentsDefinitions2020Цитирований: 0

   ABIABI:AkademIndex/openalex/2020.other.000094

8. Ustilago maydis

   National Cancer Institute

   ДругоеPlant Disease Resistance and GeneticsDefinitions2020Цитирований: 0

   ABIABI:AkademIndex/openalex/2020.other.000095

9. Seribantumab

   National Cancer Institute

   ДругоеNeutrophil, Myeloperoxidase and Oxidative MechanismsDefinitions2020Цитирований: 0

   ABIABI:AkademIndex/openalex/2020.other.000098

10. Gerbil Fibroma

    National Cancer Institute

    ДругоеShoulder and Clavicle InjuriesDefinitions2020Цитирований: 0

    ABIABI:AkademIndex/openalex/2020.other.000102